Expertise

Larry Davis, PharmD

Vice President, Medical and Clinical Affairs

EVERSANA

Larry Davis, PharmD

Larry is a pharmaceutical and biotech industry professional with over 20 years of experience in the areas of medical and clinical affairs and drug safety pharmacovigilance, as well as in quality and regulatory compliance. He has a proven record of accomplishment in building and leading high-performing teams including those for office and field-based medical affairs and for drug safety pharmacovigilance with an ability to foster and build collaborative relationships. Larry has participated in product launch planning activities including medical affairs launch readiness and support for medical/regulatory promotional review committees, managed markets, educational programs, advisory boards, key opinion leader development, publication planning, safety management teams and other cross-functional groups.

He also has extensive managed care experience as a practicing pharmacist with a clinical practice and academic teaching background. Larry obtained his Doctor of Pharmacy degree from the University of California San Francisco, School of Pharmacy, and completed a Fellowship program in medical information at the State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences.

Expertise:

Consulting (Strategy Management & Regulatory), Medical Communication Programs, Medical Information & Pharmacovigilance

Articles by Larry Davis, PharmD

Considerations for Compliance with the EU General Data Protection Regulation (GDPR)

The General Data Protection Regulation (GDPR) establishes a legal framework that sets guidelines for the collection and processing of personal information from individuals residing in the European Union (EU). GDPR compliance is a challenge for life science companies and services providers alike. Understanding and implementing compliance obligations under the GDPR is an ongoing process that […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.